|
SGTB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.25789999971815E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.58789999999054E-06 |
| Normal-vs-Stage2 |
7.59150000000375E-05 |
| Normal-vs-Stage3 |
6.88620000022233E-07 |
| Normal-vs-Stage4 |
1.18829999951053E-07 |
| Stage1-vs-Stage2 |
5.561400E-01 |
| Stage1-vs-Stage3 |
3.348600E-01 |
| Stage1-vs-Stage4 |
2.514200E-02 |
| Stage2-vs-Stage3 |
9.139000E-01 |
| Stage2-vs-Stage4 |
2.135800E-01 |
| Stage3-vs-Stage4 |
1.614230E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.76439999569567E-08 |
| Normal-vs-AfricanAmerican |
1.986730E-04 |
| Normal-vs-Asian |
7.20059999959055E-07 |
| Caucasian-vs-AfricanAmerican |
6.299600E-01 |
| Caucasian-vs-Asian |
3.963200E-01 |
| AfricanAmerican-vs-Asian |
8.905000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.36709999987161E-07 |
| Normal-vs-Female |
6.57700000017414E-07 |
| Male-vs-Female |
2.447800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.555400E-04 |
| Normal-vs-Age(41-60Yrs) |
3.86689569253917E-11 |
| Normal-vs-Age(61-80Yrs) |
3.01380000000684E-06 |
| Normal-vs-Age(81-100Yrs) |
1.443030E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.326490E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.093800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.279800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.937200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.929600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.201800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.370600E-01 |
| Classical-VS-Follicular |
4.630800E-01 |
| Classical-VS-Other |
3.201000E-01 |
| Classical-VS-Normal |
3.19550000016378E-07 |
| Tall-VS-Follicular |
8.011600E-01 |
| Tall-VS-Other |
4.111800E-01 |
| Tall-VS-Normal |
2.367000E-04 |
| Follicular-VS-Other |
6.392600E-01 |
| Follicular-VS-Normal |
2.31849999999811E-05 |
| Other-VS-Normal |
3.595800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.0634999999537E-06 |
| Normal-vs-N1 |
1.2553999995113E-07 |
| N0-vs-N1 |
1.903410E-01 |
|
|
